Oncogenic Actions of SKP2 Involves Deregulation of CDK1 Turnover Mediated by FOXM1

Anand Krishnan1, Dhanya K1, Saneesh Babu P S1

  • 1Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.

Insights

Skp2 drives tumor progression by upregulating cyclin-dependent kinase 1 (cdk1). This study uncovers new molecular mechanisms linking Skp2, p27, and FOXM1, identifying Skp2 as a potential therapeutic target for cancer.

Area of Science:

  • Cell Biology
  • Molecular Oncology

Background:

  • Cyclin-dependent kinases (cdks) regulate the cell cycle, with cdk1 being crucial.
  • Aberrant cdk1 activity is linked to tumorigenesis, but its regulatory network is not fully understood.

Purpose of the Study:

  • To investigate the functional connection between Skp2 and cdk1 turnover.
  • To elucidate the molecular mechanisms underlying Skp2-driven tumor progression.

Main Methods:

  • In vitro cell culture experiments involving Skp2 knockdown and overexpression.
  • Analysis of p27's role and the involvement of transcription factor FOXM1.
  • Correlation of in vitro findings with clinical tumor samples.

Main Results:

  • Skp2 positively regulates cdk1 expression, influencing cell cycle progression.
  • p27 partially inhibits cdk1, but concurrent Skp2 and p27 overexpression leads to cdk1 upregulation.
  • FOXM1 appears central to the Skp2-cdk1 regulatory loop.

Conclusions:

  • Discovered novel p27-independent molecular mechanisms for Skp2-mediated tumor progression.
  • Skp2's role in cdk1 regulation highlights its potential as a therapeutic target in cancer management.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K